Thrombopoietic agents: There is still much to learn

Presse Medicale

Volumn 43, Issue 4P2, 2014, Pages

  Bussel, James B ^a   Lakkaraja, Madhavi ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ELTROMBOPAG; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; ROMIPLOSTIM; THROMBOPOIETIC AGENT; THROMBOPOIETIN; UNCLASSIFIED DRUG;

BEDTIME DOSAGE; BINDING AFFINITY; BINDING SITE; CEREBROVASCULAR ACCIDENT; CHEMOTHERAPY INDUCED THROMBOCYTOPENIA; CHRONIC DISEASE; CLINICAL EFFECTIVENESS; DISEASE ASSOCIATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; EVENING DOSAGE; HEART INFARCTION; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; LIVER DISEASE; MEDICAL DECISION MAKING; MEGAKARYOCYTE; PHYSICIAN ATTITUDE; PREGNANCY; QUALITY OF LIFE; RISK ASSESSMENT; RISK FACTOR; SHORT SURVEY; THROMBOCYTE COUNT; THROMBOCYTOPOIESIS; THROMBOEMBOLISM; THROMBOSIS; TREATMENT DURATION; TREATMENT INDICATION;

HUMANS; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; THROMBOPOIETIN; TREATMENT OUTCOME;

EID: 84898851537     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lpm.2014.02.008     Document Type: Short Survey

References (31)

1. Olnes M.J., Scheinberg P., Calvo K.R., Desmond R., Tang Y., Dumitriu B., et al. Eltrombopag and improved hematopoiesis in refractory aplastic anemia. New Engl J Med 2012, 367:11-19.
2. Pecci A., Gresele P., Klersy C., Savoia A., Noris P., Fierro T., et al. Eltrombopag for the treatment of the inherited thrombocytopenia deriving from MYH9 mutations. Blood 2010, 116:5832-5837.
3. Kuter D.J., Begley C.G. Recombinant human thrombopoietin: basic biology and evaluation of clinical studies. Blood 2002, 100:3457-3469.
4. Bussel J.B., Kuter D.J., George J.N., McMillan R., Aledort L.M., Conklin G.T., et al. AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. New Engl J Med 2006, 355:1672-1681.
5. Kuter D.J., Bussel J.B., Lyons R.M., Pullarkat V., Gernsheimer T.B., Senecal F.M., et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet 2008, 371:395-403.
6. Kuter D.J., Rummel M., Boccia R., Macik B.G., Pabinger I., Selleslag D., et al. Romiplostim or standard of care in patients with immune thrombocytopenia. New Engl J Med 2010, 363:1889-1899.
7. Kuter D.J., Bussel J.B., Newland A., Baker R.I., Lyons R.M., Wasser J., et al. Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy. Br J Haematol 2013, 161:411-423.
8. Bussel J.B., Cheng G., Saleh M.N., Psaila B., Kovaleva L., Meddeb B., et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. New Engl J Med 2007, 357:2237-2247.
9. Bussel J.B., Provan D., Shamsi T., Cheng G., Psaila B., Kovaleva L., et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. Lancet 2009, 373:641-648.
10. Cheng G., Saleh M.N., Marcher C., Vasey S., Mayer B., Aivado M., et al. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet 2011, 377:393-402.
11. Saleh M.N., Bussel J.B., Cheng G., Meyer O., Bailey C.K., Arning M., et al. Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study. Blood 2013, 121:537-545.
12. Kopp H.G., Hooper A.T., Broekman M.J., Avecilla S.T., Petit I., Luo M., et al. Thrombospondins deployed by thrombopoietic cells determine angiogenic switch and extent of revascularization. J Clin Invest 2006, 116:3277-3291.
13. McHutchison J.G., Dusheiko G., Shiffman M.L., Rodriguez-Torres M., Sigal S., Bourliere M., et al. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. New Engl J Med 2007, 357:2227-2236.
14. Rice L., Nichol J.L., McMillan R., Roskos L.K., Bacile M. Cyclic immune thrombocytopenia responsive to thrombopoietic growth factor therapy. Am J Hematol 2001, 68:210-214.
15. Khellaf M., Viallard J.F., Hamidou M., Cheze S., Roudot-Thoraval F., Lefrere F., et al. A retrospective pilot evaluation of switching thrombopoietic receptor-agonists in immune thrombocytopenia. Haematologica 2013, 98:881-887.
16. Bao W., Bussel J.B., Heck S., He W., Karpoff M., Boulad N., et al. Improved regulatory T-cell activity in patients with chronic immune thrombocytopenia treated with thrombopoietic agents. Blood 2010, 116:4639-4645.
17. Bussel J.B., Wang X., Eisen M. Case studies of remission in adults with immune thrombocytopenia (ITP) following cessation of treatment with the tpo receptor agonist romiplostim. 55th ASH Annual Meeting and Exposition 2013, http://ash.confex.com/ash/2013/webprogram/Paper57069.html.
18. Bussel J.B., Buchanan G.R., Nugent D.J., Gnarra D.J., Bomgaars L.R., Blanchette V.S., et al. A randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopenia. Blood 2011, 118:28-36.
19. Leven E., Ramaswamy K., McGuinn C.E., Nugent D., Bussel J.B. Safe and effective use of romiplostim and eltrombopag in children with ITP. 55th ASH Annual Meeting and Exposition 2013, http://ash.confex.com/ash/2013/webprogram/Session5140.html.
20. George J.N., Mathias S.D., Go R.S., Guo M., Henry D.H., Lyons R., et al. Improved quality of life for romiplostim-treated patients with chronic immune thrombocytopenic purpura: results from two randomized, placebo-controlled trials. Br J Haematol 2009, 144:409-415.
21. Klaassen R.J., Mathias S.D., Buchanan G., Bussel J., Deuson R., Young N.L., et al. Pilot study of the effect of romiplostim on child health-related quality of life (HRQoL) and parental burden in immune thrombocytopenia (ITP). Pediatr Blood Cancer 2012, 58:395-398.
22. Mathias S.D., Bussel J.B., George J.N., McMillan R., Okano G.J., Nichol J.L. A disease-specific measure of health-related quality of life for use in adults with immune thrombocytopenic purpura: its development and validation. Health Qual Life Outcomes 2007, 5:11.
23. Kantarjian H., Fenaux P., Sekeres M.A., Becker P.S., Boruchov A., Bowen D., et al. Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia. J Clin Oncol 2010, 28:437-444.
24. Bussel J.B., Kuter D.J., Pullarkat V., Lyons R.M., Guo M., Nichol J.L. Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. Blood 2009, 113:2161-2171.
25. Psaila B., Bussel J.B., Linden M.D., Babula B., Li Y., Barnard M.R., et al. In vivo effects of eltrombopag on platelet function in immune thrombocytopenia: no evidence of platelet activation. Blood 2012, 119:4066-4072.
26. Ghanima W., Lee S.Y., Barsam S., Miller A., Sandset P.M., Bussel J.B. Venous thromboembolism and coagulation activity in patients with immune thrombocytopenia treated with thrombopoietin receptor agonists. Br J Haematol 2012, 158:811-814.
27. Ghanima W., Junker P., Hasselbalch H.C., Boiocchi L., Geyer J.T., Feng X., et al. Fibroproliferative activity in patients with immune thrombocytopenia (ITP) treated with thrombopoietic agents. Br J Haematol 2011, 155:248-255.
28. Barsam S.J., Psaila B., Forestier M., Page L.K., Sloane P.A., Geyer J.T., et al. Platelet production and platelet destruction: assessing mechanisms of treatment effect in immune thrombocytopenia. Blood 2011, 117:5723-5732.
29. Ghanima W., Geyer J.T., Lee C.S., Boiocchi L., Imahiyerobo A.A., Orazi A., et al. Bone marrow fibrosis in 66 Immune Thrombocytopenia patients treated with thrombopoietin receptor agonists: a single center long-term follow-up. Haematologica 2014, Epub ahead of print. 10.3324/haematol.2013.098921.
30. Terrell D.G.J., Bussel J.B., Lyons R.M., Pullarkat V., Redner R.L., Selleslag D., et al. Self-Administration of romiplostim in patients with chronic immune thrombocytopenia (ITP). Community Oncol 2013, 10:285-292.
31. Ghanima W., Godeau B., Cines D.B., Bussel J.B. How I treat immune thrombocytopenia: the choice between splenectomy or a medical therapy as a second-line treatment. Blood 2012, 120:960-969.